- Reports /
- RSV Diagnostics Market
RSV Diagnostics Market
RSV Diagnostics Market Market Research Report – Segmented By Product (Kits and Assays, Instruments, Other Products), By Method (Molecular Diagnostics, Rapid Antigen Detection Tests, Other Methods), By End User (Hospitals and Clinics, Clinical Laboratories, Home Care), By Region (North America, Europe, APAC, RoW) & Region (North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America) – Analysis on Size, Share, Trends, COVID-19 Impact, Competitive Analysis, Growth Opportunities and Key Insights from 2019 to 2027.
Table of contents
- Executive Summary
- Market Overview
- Industry Analysis
- Market Analysis
- By Product
- By Method
- By End User
- By Region
- North America
- Europe
- Asia-Pacific
- Middle-East & Africa
- Latin America
- Company Analysis
- Competitive Analysis
- Research Methodology
- Appendix
Executive Summary
RSV Diagnostics Market was valued at US $913.91 million in 2021 and is projected to grow at 9.81% CAGR over the forecast period to reach US $1,601.97 million by 2027. RSV Diagnostics Market represented US $155.94 million opportunity over 2019-2021 and estimated to create US $688.05 million opportunity in 2027 over 2021.
RSV Diagnostics from Consainsights analyses the RSV Diagnostics Market in the Life Sciences industry over the forecast period to 2027.
RSV Diagnostics research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.
RSV Diagnostics segmentation includes Product, Method, End User, Region and Geography.
Based on the Product, the RSV Diagnostics analysis covers Kits and Assays, Instruments, Other Products.
In Product segment, Kits and Assays segment has highest cagr growth of 8.67%.
Based on the Method, the RSV Diagnostics analysis covers Molecular Diagnostics, Rapid Antigen Detection Tests, Other Methods.
In Method segment, Molecular Diagnostics segment has highest cagr growth of 8.67%.
Based on the End User, the RSV Diagnostics analysis covers Hospitals and Clinics, Clinical Laboratories, Home Care.
In End User segment, Hospitals and Clinics segment has highest cagr growth of 8.67%.
Based on the Region, the RSV Diagnostics analysis covers North America, Europe, APAC, RoW.
In Region segment, North America segment has highest cagr growth of 8.67%.
Based on the region, the RSV Diagnostics analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.
Key companies operating in the market include Biomérieux, Becton, Dickinson and Company (BD), Abbott, Roche, Danaher, Thermo Fisher, Biocartis, Luminex, Hologic, Fast Track Diagnostics and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.
Market Overview
Definition & Scope
The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.
The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.
The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.
Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.
Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.
As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.
Currency, Year & Forecast
The currency used in this report is USD, with the market size indicated in terms of USD million/billion.
For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.
For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.
Product
Introduction
In 2021, Kits and Assays segment has the highest revenue of US $486.36 million and is expected to grow at CAGR of 8.67% by 2027 Kits and Assays segment has highest cagr growth of 8.67%.
Kits and Assays
Kits and Assays segment was valued at US $403.38 million in 2019 and is projected to grow at 8.67% CAGR over the forecast period to reach US $852.53 million by 2027. Kits and Assays segment represented US $82.99 million opportunity over 2019-2021 and estimated to create US $366.17 million opportunity in 2027 over 2021.
Instruments
Instruments segment was valued at US $228.04 million in 2019 and is projected to grow at 8.67% CAGR over the forecast period to reach US $481.96 million by 2027. Instruments segment represented US $46.91 million opportunity over 2019-2021 and estimated to create US $207.00 million opportunity in 2027 over 2021.
Other Products
Other Products segment was valued at US $126.56 million in 2019 and is projected to grow at 8.67% CAGR over the forecast period to reach US $267.48 million by 2027. Other Products segment represented US $26.04 million opportunity over 2019-2021 and estimated to create US $114.88 million opportunity in 2027 over 2021.
Method
Introduction
In 2021, Molecular Diagnostics segment has the highest revenue of US $613.65 million and is expected to grow at CAGR of 8.67% by 2027 Molecular Diagnostics segment has highest cagr growth of 8.67%.
Molecular Diagnostics
Molecular Diagnostics segment was valued at US $508.94 million in 2019 and is projected to grow at 8.67% CAGR over the forecast period to reach US $1,075.64 million by 2027. Molecular Diagnostics segment represented US $104.70 million opportunity over 2019-2021 and estimated to create US $461.99 million opportunity in 2027 over 2021.
Rapid Antigen Detection Tests
Rapid Antigen Detection Tests segment was valued at US $218.73 million in 2019 and is projected to grow at 8.67% CAGR over the forecast period to reach US $462.29 million by 2027. Rapid Antigen Detection Tests segment represented US $45.00 million opportunity over 2019-2021 and estimated to create US $198.56 million opportunity in 2027 over 2021.
Other Methods
Other Methods segment was valued at US $30.30 million in 2019 and is projected to grow at 8.67% CAGR over the forecast period to reach US $64.04 million by 2027. Other Methods segment represented US $6.23 million opportunity over 2019-2021 and estimated to create US $27.50 million opportunity in 2027 over 2021.
End User
Introduction
In 2021, Hospitals and Clinics segment has the highest revenue of US $662.66 million and is expected to grow at CAGR of 8.67% by 2027 Hospitals and Clinics segment has highest cagr growth of 8.67%.
Hospitals and Clinics
Hospitals and Clinics segment was valued at US $549.59 million in 2019 and is projected to grow at 8.67% CAGR over the forecast period to reach US $1,161.55 million by 2027. Hospitals and Clinics segment represented US $113.07 million opportunity over 2019-2021 and estimated to create US $498.89 million opportunity in 2027 over 2021.
Clinical Laboratories
Clinical Laboratories segment was valued at US $206.98 million in 2019 and is projected to grow at 8.67% CAGR over the forecast period to reach US $437.45 million by 2027. Clinical Laboratories segment represented US $42.58 million opportunity over 2019-2021 and estimated to create US $187.89 million opportunity in 2027 over 2021.
Home Care
Home Care segment was valued at US $1.41 million in 2019 and is projected to grow at 8.67% CAGR over the forecast period to reach US $2.97 million by 2027. Home Care segment represented US $0.29 million opportunity over 2019-2021 and estimated to create US $1.28 million opportunity in 2027 over 2021.
Region
Introduction
In 2021, North America segment has the highest revenue of US $426.72 million and is expected to grow at CAGR of 8.67% by 2027 North America segment has highest cagr growth of 8.67%.
North America
North America segment was valued at US $353.91 million in 2019 and is projected to grow at 8.67% CAGR over the forecast period to reach US $747.99 million by 2027. North America segment represented US $72.81 million opportunity over 2019-2021 and estimated to create US $321.27 million opportunity in 2027 over 2021.
Europe
Europe segment was valued at US $204.48 million in 2019 and is projected to grow at 8.67% CAGR over the forecast period to reach US $432.17 million by 2027. Europe segment represented US $42.07 million opportunity over 2019-2021 and estimated to create US $185.62 million opportunity in 2027 over 2021.
APAC
APAC segment was valued at US $126.32 million in 2019 and is projected to grow at 8.67% CAGR over the forecast period to reach US $266.98 million by 2027. APAC segment represented US $25.99 million opportunity over 2019-2021 and estimated to create US $114.67 million opportunity in 2027 over 2021.
RoW
RoW segment was valued at US $73.26 million in 2019 and is projected to grow at 8.67% CAGR over the forecast period to reach US $154.83 million by 2027. RoW segment represented US $15.07 million opportunity over 2019-2021 and estimated to create US $66.50 million opportunity in 2027 over 2021.